

β -ENDORPHIN: STRUCTURE-ACTIVITY RELATIONSHIPS IN THE
GUINEA PIG ILEUM AND OPIATE RECEPTOR BINDING ASSAYS

Byron A. Doneen, David Chung, Donald Yamashiro,
Ping Yee Law*, Horace H. Loh* and Choh Hao Li

Hormone Research Laboratory and *Department of Pharmacology, University
of California, San Francisco, California 94143

Received November 29, 1976

SUMMARY: The opiate activities of some derivatives and enzymatic digests of camel and human β -endorphin were determined in the guinea pig ileum and rat brain opiate receptor binding assays. Derivatives of β -endorphins altered within the amino-terminal five residues showed pronounced losses in activity. Anisylation of the C-terminal glutamic acid residue of β_h -endorphin produced only small reductions in activity. Chymotryptic digestion greatly weakened the opiate activities of β_h -endorphin, whereas carboxypeptidase A, tryptic and leucine aminopeptidase digests showed only small losses in potency. The C-terminus of β -endorphin appears to contribute little directly to opiate activity. Amino acid analysis and assay of the leucine aminopeptidase digests suggest that the larger potency of β -endorphin relative to Met-enkephalin may be a consequence of its greater resistance to exopeptidase attack.

Several peptides which are endogenous ligands for the opiate receptors of brain have been isolated. Two pentapeptides, named Met- and Leu-enkephalin, have been purified from porcine and bovine brain (1,2). Li and Chung (3) reported the isolation and structure of a thirty-one amino acid peptide (β -endorphin) from the camel pituitary with potent opiate activities. The homologous untriakontapeptides have also been identified in the pituitary glands of the pig (4), sheep (5), and human (5,6). α - and γ -Endorphins have been characterized from the pig neurohypophysis-hypothalamus (7). The amino acid sequences of Met-enkephalin, α - and γ -endorphins, and β -endorphins are contained within the sequence of pituitary β -LPH (8,9) and correspond to β -LPH-(61-65), -(61-76), -(61-77), and -(61-91), respectively. Each of these peptides possess substantial morphine-like

Abbreviations: Met-enkephalin, methionine enkephalin; β_c -endorphin, camel β -endorphin; β_h -endorphin, human β -endorphin; β_c -MSH, camel β -melanotropin; β_s -LPH, sheep β -lipotropin; β -LPH-(61-65), -(61-76), etc., that peptide corresponding to residues (61-65), -(61-76), etc., of the sequence of β -lipotropin.

activities when measured in vitro as in the guinea pig ileum assay, or as specific binding to brain opiate receptors (1,2,6,7). However, they display widely different opiate activities when measured in vivo. Met- and Leu-enkephalins and α -endorphin display weak transient analgesic action after intracranial injection in mice or rats (10-13). In contrast, β -endorphin has potent analgesic action when injected centrally (12) or intravenously (13).

Structure-activity relationships have shown the importance of the Tyr¹, Phe⁴ and Met⁵ or Leu⁵ residues for the in vitro opiate activities of enkephalins (14-17). We have analyzed for the first time the structure-activity relationships of β -endorphin by guinea pig ileum and rat brain opiate receptor assays. Results of these studies are reported herein.

Materials and Methods

β _C-Endorphin (18), β _h-endorphin (19) and β _C-MSH (20) were synthesized by the solid-phase method. β _S- and β _h-LPH were purified as previously described (8,9). β _h-LPH-(61-69) was one of the tryptic fragments (T-17) utilized in the amino acid sequence determination of β _h-LPH (9). Met-enkephalin was purchased from Bachem Laboratories (Marina del Reyes, Ca.).

Acetone-treated β _h-endorphin was prepared by reaction of 12.8 mg of the peptide in 50% aqueous acetone (20 ml) for 21 hr at 24°. Partition chromatography on Sephadex G-50 in 1-butanol-pyridine-0.6 M NH₄OAc (5:3:10) gave essentially one peak with R_f 0.48 (R_f of β _h-endorphin, 0.37) and 9.1 mg of product. On paper electrophoresis (pH 3.7, 400 V, 4 hr) the substance behaved as a more acidic material (R_f 0.48 relative to lysine as compared to R_f 0.54 for β -endorphin). A sample heated in 0.1% acetic acid for 10 min at 100° liberated acetone. All these properties parallel the behavior of acetone-oxytocin whose structure (21) consists of an isopropylidene bridge between the N-terminal amino group and the nitrogen of the peptide bond between sequence positions 1 and 2.

(Anisylated-Glu³¹)- β _h-endorphin was isolated as a by-product in the synthesis of β _h-endorphin (19) and was further purified by partition chromatography on Sephadex G-50 in 1-butanol-pyridine-0.1% acetic acid (5:3:11) in which it gave a R_f of 0.53. Amino acid analysis, ultraviolet spectral analysis and peptide mapping indicated an anisylated glutamic acid residue (22) at the C-terminus.

(Homoserine⁵)- β _h-endorphin was produced by dissolving 10 mg β _h-endorphin in 0.5 ml 70% formic acid followed by addition of 20 mg CNBr (Eastman Organic). After stirring at 24° for 24 hr in the dark, the solution

was diluted with a large volume of water and lyophilized. Peptide mapping and end-group analysis showed that no cleavage occurred. The Met-Thr bond has previously been shown to be resistant to CNBr cleavage in 70% formic acid (23). The amino acid analysis indicated that Met⁵ was converted to homoserine by CNBr. Formic acid treated- β_h -endorphin was produced as above except no CNBr was added.

Carboxypeptidase A digestion of β_h -endorphin was done by dissolving 1.6 mg of β_h -endorphin in 0.1 ml, pH 8.5, Tris-HCl buffer and adding 0.05 mg carboxypeptidase A (Worthington). The suspension was incubated at 37° for 8 hr and the peptide recovered by lyophilization.

Tryptic digestion of β_h -endorphin was performed by dissolving 1.1 mg β_h -endorphin in 0.2 ml 0.2 M NH₄ OAc buffer (pH 8.0). Trypsin (Serva), 0.02 mg, was added and the solution incubated at 37° for 8 hr. The reaction was stopped by addition of 1.8 ml 0.05 N HCl. Chymotryptic digestion of β_h -endorphin was done as above except that chymotrypsin (Calbiochem) was used.

Leucine aminopeptidase digested peptides were prepared as follows: β_c -endorphin (0.34 mg) and Met-enkephalin (0.06 mg) were each dissolved in 0.1 ml pH 8.5 Tris buffer. Leucine aminopeptidase (0.007 mg, Worthington) was added to both samples, and the solutions incubated for 2 hr at 37°. The digests were acidified to pH 3, lyophilized, and portions removed for amino acid analysis.

Narcotic agonist activities were measured from the depression of electrically-stimulated contractions of the guinea pig ileum prepared as previously described (24). Briefly, a 2-3 cm segment of ileum was mounted between internal and external platinum electrodes in a 25 ml bath containing Krebs's solution (with 125 nM diphenylamine as antihistamine) at 37° and aerated with 95% O₂/5% CO₂. Tension changes evoked by rectilinear electrical pulses (0.4 msec duration, 0.1 Hz, 80 V) were recorded by a Grass Isometric Pressure Transducer (tension, 2 g) coupled to a model 7 Grass Polygraph. Peptides and normorphine were assayed on two ileum preparations at 3-5 concentrations.

Opioid activity was also assayed as the inhibition of stereospecific [³H]-morphine (New England Nuclear, 10 Ci/mmol) binding to lysed rat synaptic plasma membranes prepared essentially as described (25). Synaptic plasma membranes (200 μ g protein) were preincubated in 2 ml sodium-free HEPES buffer (26 mM, pH 7.5) at 25° for 10 min with peptides, morphine sulfate or dextrorphan. Next [³H]-morphine was added (4 nM) and the incubation continued for 15 min. Assays were terminated by filtration followed by three 4 ml rinses with ice-cold buffer on glass fiber filters (Whatman GF/c). Filters were dried and counted by liquid scintillation spectrophotometry. Stereospecific opiate binding, the difference between [³H]-morphine binding in the presence of dextrorphan (1 x 10⁻⁶M) and morphine sulfate (1 x 10⁻⁶M) was 45% of the total binding. Peptides were assayed in quadruplicate; standard errors of the mean c.p.m. were always less than 6%.

Potencies of peptides in both assays were calculated as the ratio of the IC₅₀ (inhibiting molar concentration - 50%) to that of β_c -endorphin.

Table I

Opiate Activities of β_c -Endorphin and Related Peptides

Preparation	Relative Potency* in	
	Guinea pig ileum	Brain opiate receptor binding
β_c -endorphin	1.00	1.00
β_h -endorphin	1.00	1.00
Met-enkephalin	0.25	0.34
Normorphine	0.65	---
β_s -LPH	< 0.01	< 0.01
β_h -LPH	< 0.01	< 0.01
β_c -MSH	< 0.01	< 0.01
β_h -LPH-(61-69)	0.20	0.26
Acetone treated β_h -endorphin	0.01	0.02
(anisylated-Glu ³¹)- β_h -endorphin	0.76	0.75
Formic acid-treated- β_h -endorphin	1.00	1.00
(5-homoserine)- β_h -endorphin	< 0.01	< 0.01
β_h -endorphin: Carboxypeptidase A digest	1.00	1.00
β_h -endorphin: Chymotryptic digest	0.13	0.03
β_h -endorphin: Tryptic digest	0.71	0.61
β_c -endorphin: Leucine aminopeptidase digest	0.97	0.93
Met-enkephalin: Leucine aminopeptidase digest	< 0.01	< 0.01

* Potency of β_c -endorphin is defined as 1.00. Other preparations were compared to β_c -endorphin standard on a molar basis. IC_{50} of β_c -endorphin: $2.5-8.0 \times 10^{-8}$ M in the guinea pig ileum assay; $1.2-3.7 \times 10^{-7}$ M in the rat brain opiate receptor binding assay.

Results and Discussion

Opiate activities of the various peptides and enzymatic digests relative to β_c -endorphin as measured in the guinea pig ileum and rat brain receptor assays are summarized in Table I. In the ileum assay β_c - and β_h -endorphins were each

55% more potent than normorphine, and 4-times more active than Met-enkephalin. Similarly in the opiate receptor assay, Met-enkephalin had reduced potency (34%) compared to β -endorphins. β_h -LPH-(61-69), corresponding to β_h -endorphin-(1-9), was somewhat less potent than Met-enkephalin, as previously observed (11, 26). In contrast, β_s - and β_h -LPH and β_c -MSH showed no activity in either assay, even when tested at the high concentration of 5.0×10^{-6} M (see also 26). β_s -LPH and β_c -MSH also failed to show naloxone-like antagonism to normorphine or β_c -endorphin in the ileum (data not shown).

Acetone treated β_h -endorphin, cyclized between Tyr¹-Gly² by a bridge which incorporates the amino group of Tyr¹, displayed only 1% (ileum) and 2% (opiate receptor assay) of β_h -endorphin activity. β_h -Endorphin, anisylated at its C-terminal glutamic acid residue, showed a modest decline in opiate activities. Whereas its amino-terminal Tyr may be essential, the carboxyl-terminal glutamic acid residue appears to contribute little directly to the interaction of β_h -endorphin with opiate receptors. In addition, conversion of Met⁵ to 5-homoserine abolished the opiate activities of β_h -endorphin.

Hydrolysis of β_h -endorphin with chymotrypsin diminished considerably its potency in both assays. Chymotrypsin can be expected to cleave β_h -endorphin at Phe⁴ as well as at other aromatic residues. On the other hand, digestion of β_h -endorphin with enzymes having no specificity within the amino-terminal five residues had no (carboxypeptidase A) or limited (trypsin) effects on in vitro opiate activities. Carboxypeptidase A has been shown to cleave the Gly⁹⁰-Gln⁹¹ dipeptide from porcine LPH-(61-91) (4), indicating again the non-essential nature of these residues for opiate action. Trypsin digestion, however, reduced somewhat β_h -endorphin potency in ileum (71%) and opiate receptor binding (61%). Interestingly, these reduced activities were still greater than the activities of the nonapeptide β_h -LPH-(61-69), which can be expected to be produced by the action of trypsin on

β_h -endorphin. Therefore, the trypsin digest contains undigested β_h -endorphin or some other tryptic fragment, or fragments in combination, having opiate activity.

β_c -Endorphin was susceptible to very limited hydrolysis with leucine aminopeptidase as indicated by liberation of only trace amounts of tyrosine as detected by amino acid analysis. As shown in Table 1, this enzyme digest of β_c -endorphin showed only slight diminution of opiate activities; in contrast, Met-enkephalin, which showed stoichiometric hydrolysis of the Tyr¹-Gly² bond, lost all activity after leucine aminopeptidase digestion. Therefore, the amino terminal residue of β_c -endorphin appears to differ from that of Met-enkephalin by being protected from exopeptidase attack. Enzymes in brain and plasma are known to rapidly inactivate enkephalins (27), but digest less readily the more potent [D-Ala²]-Met-enkephalin (28). The greater analgesic potency of β -endorphin compared to Met-enkephalin in vivo may result in part from its greater resistance, especially at its amino-terminus, to enzymic digestion.

Acknowledgements. This work was supported in part by a grant from the National Institutes of Health (GM-2907) and NIDA grants (DA-01314 and DA-00564). B.A.D. is a recipient of a Fellowship from the National Institute of Arthritis, Metabolism and Digestive Diseases.

References

1. Hughes, J., Smith, T. W., Kosterlitz, H. W., Fothergill, L. A., Morgan, B. A. and Morris, H. R. (1975) *Nature* 258, 577-579.
2. Simantov, R. and Snyder, J. H. (1976) *Proc. Natl. Acad. Sci. USA* 73, 2515-2519.
3. Li, C. H. and Chung, D. (1976) *Proc. Natl. Acad. Sci. USA* 73, 1145-1148.
4. Bradbury, A. F., Smyth, D. G., Snell, C. R., Birdsall, N.J.M. and Hulme, C. E. (1976) *Nature* 260, 793-795.
5. Chrétien, M., Benjannet, S., Dragon, N., Seidah, N. G. and Lis, M. (1976) *Biochem. Biophys. Res. Commun.* 72, 472-478.
6. Li, C. H., Chung, D. and Doneen, B. A. (1976) *Biochem. Biophys. Res. Commun.* 72, 1542-1547.
7. Guillemin, R., Ling, N. and Burgus, R. (1976) *Séances Acad. Sci. Ser. D.* 282, 783-785.

8. Li, C. H., Barnafi, L., Chrétien, M. and Chung, D. (1966) *Excerpta Med. Int. Congr. Ser.*, 111, 349-364.
9. Li, C. H. and Chung, D. (1976) *Nature* 260, 622-624.
10. Belluzzi, J. D., Grant, N., Garsky, V., Sarantakis, D., Wise, C. O. and Stein, L. (1976) *Nature* 260, 626-627.
11. Gráf, L., Romai, A. Z., Bajusz, S., Cseh, G. and Székely, J. I. (1976) *FEBS Letters* 64, 181-184.
12. Loh, H. H., Tseng, L. F., Wei, E. and Li, C. H. (1976) *Proc. Natl. Acad. Sci. USA* 73, 2895-2898.
13. Tseng, L. F., Loh, H. H. and Li, C. H. (1976) *Nature* 263, 239-240.
14. Chang, J-K., Fong, B.T.W., Pert, A. and Pert, C. B. (1976) *Life Sci.* 18, 1473-1482.
15. Day, A. R., Luján, M., Dewey, W. L., Harris, L. S., Redding, J. A. and Freer, R. J. (1976) *Res. Commun. Chem. Path. Pharmacol.* 14, 597-603.
16. Terenius, L., Wohlström, A., Lindeberg, G., Karlsson, S. and Ragnarsson, U. (1976) *Biochem. Biophys. Res. Commun.* 71, 175-179.
17. Ling, N. and Guillemin, R. (1976) *Proc. Natl. Acad. Sci. USA* 73, 3308-3310.
18. Li, C. H., Lemaire, S., Yamashiro, D. and Doneen, B. A. (1976) *Biochem. Biophys. Res. Commun.* 71, 19-25.
19. Li, C. H., Yamashiro, D., Tseng, L-F., and Loh, H. H. (1976) *J. Med. Chem.* (in press).
20. Li, C. H., Yamashiro, D. and Lemaire, S. (1975) *Biochem.* 14, 953-956.
21. Hruby, V. J., Yamashiro, D. and du Vigneaud, V. (1968) *J. Amer. Chem. Soc.* 90, 7106-7110.
22. Feinberg, R. S. and Merrifield, R. B. (1975) *J. Amer. Chem. Soc.* 97, 3485-3496.
23. Schroeder, W. A., Shelton, J. B. and Shelton, J. R. (1969) *Arch. Biochem. Biophys.* 130, 551-556.
24. Kosterlitz, H. W., Lydon, R. T. and Watt, A. F. (1970) *Brit. J. Pharmacol* 39, 398-413.
25. Whittaker, V. P. and Sheridan, M. N. (1965) *J. Neurochem.* 12, 363-372.
26. Cox, B. M., Goldstein, A. and Li, C. H. (1976) *Proc. Natl. Acad. Sci. USA* 73, 1821-1823.
27. Hambrook, J. M., Morgan, B. A., Rance, M. J. and Smith, C.F.C. (1976) *Nature* 262, 782.
28. Pert, C. B., Pert, A., Chang, J-K., and Fong, B.T.W. (1976) *Science* 194, 330-332.